Ucl Business Plc

The Institute of Ophthalmology

Other

University of Florida Research Foundation, Incorporated

Ocular Instruments, Inc.

Moorfields Eye Hospital Nhs Trust

Optceutics Limited

Peng Tee Khaw

Gloria Astrid Limb

Gregory Scott Schultz

Stephen James Brocchini

Peter G Harrington

Daniel M Bell

Yann Bouremel

Nkiruka Ibeanu

Ashkan Khalili

Sahar Awwad

An artificial eye assembly () comprising: —an anterior layer () comprising an anterior cavity (); —a flow constricting () layer comprising a first aperture (), and wherein the first aperture () is in fluid communication with the anterior cavity (); —a shaping layer () comprising a second aperture and a shaping structure (), wherein the shaping structure () is located within, partially within, or outside of the second aperture, and wherein the shaping structure comprises () one or more webs (), the webs () connecting the structure () to the rest of the shaping layer (), and wherein the second aperture is in fluid communication with the first aperture (); —a flow resistive layer () comprising pores, and wherein pores of the layer are in fluid communication with the second aperture; —a posterior layer () comprising a posterior cavity (), and wherein the posterior cavity () is in fluid communication with pores of the flow resistive layer (); —a fluid inlet () located in the anterior and/or posterior cavity (), or located in or adjacent to the second aperture; —a fluid outlet () located in the anterior cavity; and —an injection inlet () located in the posterior cavity and/or located in the anterior cavity, and wherein the anterior cavity () and the posterior cavity () are in fluid communication with one another via a fluid path formed through the layers (); and wherein, in use, a fluid introduced under pressure into the assembly via the fluid inlet () will flow along the fluid path and exit the assembly via the fluid outlet () with a first flow rate.

Artificial eye assembly for studying ocular pharmacokinetics

Speculum

Punch

Forceps

Grippers

A solid, compressed pharmaceutical composition comprises i) a peptide active pharmaceutical ingredient, ii) a polysaccharide excipient and/or an albumin, and iii) an oligosaccharide excipient. The polysaccharide excipient may be hyaluronic acid, or the potassium salt thereof, and the oligosaccharide excipient may be trehalose.

Composition for intraocular implantation of bevacizumab

A method for the production of retinal cells, useful in transplantation therapy, comprises: (i) obtaining one or more mammalian adult M&#xfc;ller cells; and (ii) culturing the cells in the presence of an extracellular matrix protein and a growth factor to thereby induce dedifferentiation of the M&#xfc;ller cells into a progenitor phenotype.

Transplantation of cells expressing markers for photoreceptor cells and retinal ganglion cells induced from M&#xfc;ller stem cells

Muller cells de-differentiated to cells expressing markers of neural cell progenitors

A gonioscopy lens employs a plurality of mirror sets so that substantially the entire periphery of the anterior chamber of an eye can be viewed without rotating or moving the contact lens. Each mirror set comprises a first mirror position anterior to the eye on one side of the optical axis and a second mirror positioned posterior to the first mirror on the opposite side of the optical axis. Each set is oriented relative to each other so that the second mirror receives light rays from the peripheral portion of the anterior chamber, reflects those rays to the second mirror to the first mirror, and then reflects the light rays in a generally anterior direction so that they can be used by an ophthalmologist employing the lens. The image viewed by the ophthalmologist is upright and located over its actual position.

Gonioscopy lens

The use of an MMP inhibitor, especially a collagenase inhibitor, in the manufacture of a medicament for the treatment of a natural or artificial tissue comprising extracellular matrix components to inhibit contraction of the tissue and methods for the treatment of tissue comprising extracellular matrix components to inhibit contraction.

Medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction

Medical use of matrix metalloproteinase inhibitors for inhibiting tissue

Growing community of inventors

London, United Kingdom

Peng Tee Khaw